SCHEMBL23440341

SCHEMBL23440341

O=C(NCc1ccco1)c1ccccc1NSc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ TP53 P04637 1/20 0.61
▸ HPGD P15428 8/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ KDM4E B2RXH2 5/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MAPT P10636 2/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ SENP6 Q9GZR1 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ HTT P42858 3/20 0.54
▸ POLB P06746 3/20 0.54
▸ LMNA P02545 2/20 0.53
▸ GFER P55789 1/20 0.53
▸ USP2 O75604 1/20 0.52
▸ RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23440431 0.91 NPSR1 (0.60) SMN1; SMN2HPGDALDH1A1KDM4EMEN1
SCHEMBL23440433 0.89 TDP1 (0.58) SMN1; SMN2HPGDALDH1A1KDM4EMEN1
SCHEMBL23439713 0.89 HPGD (0.60) SMN1; SMN2HPGDALDH1A1KDM4EMEN1
SCHEMBL23440348 0.85 HPGD (0.60) SMN1; SMN2TP53HPGDALDH1A1KDM4E
SCHEMBL23440346 0.84 HPGD (0.56) SMN1; SMN2HPGDALDH1A1KDM4EMEN1
SCHEMBL23439800 0.81 HPGD (0.51) SMN1; SMN2TP53HPGDALDH1A1KDM4E
SCHEMBL23440117 0.81 HPGD (0.51) SMN1; SMN2TP53HPGDALDH1A1KDM4E
SCHEMBL23440327 0.80 HPGD (0.55) SMN1; SMN2TP53HPGDALDH1A1KDM4E
SCHEMBL23413024 0.79 ALDH1A1 (0.69) SMN1; SMN2TP53HPGDALDH1A1KDM4E
SCHEMBL30092886 0.79 ALDH1A1 (0.69) SMN1; SMN2TP53HPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021105906-A1 ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE GAIN THERAPEUTICS SA (CH) 2021-06-03 — — WO disclosed
Send feedback